|
Encysive Pharmaceuticals Announces Launch of THELIN (Sitaxentan Sodium) in the Netherlands Monday April 16, 2:00 am ET First Selective, Once-Daily Oral Endothelin A Receptor Antagonist Now Commercially Available for Pulmonary Arterial Hypertension Patients HOUSTON, April 16, 2007 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals (NasdaqGM:ENCY - News) today announced the commercial availability of THELIN(r)(1) (sitaxentan sodium(2)) 100 mg tablets in the Netherlands for the treatment of pulmonary arterial hypertension (PAH). The Company received European Union marketing authorization for THELIN from the European Commission in August 2006. THELIN is the first selective endothelin A receptor antagonist and the first once-daily oral treatment available for patients with PAH. ADVERTISEMENT click here THELIN is indicated for improving exercise capacity in PAH patients classified as World Health Organization (WHO) functional class III. Efficacy has been shown in primary pulmonary hypertension(3) and pulmonary hypertension associated with connective tissue disease (CTD). ``As a once-daily oral therapy, THELIN may provide PAH patients with effective symptom management in a convenient, non-invasive route of administration,'' said Anco Boonstra, M.D., Ph.D., pulmonologist, Vrije Universiteit Medical Center, Amsterdam. ``THELIN is a welcome new treatment option for patients with primary disease and also those with CTD-related PAH, where THELIN has demonstrated a therapeutic benefit.'' The European Commission's centralized licensing procedure permits Encysive to market THELIN in all 27 member states of the European Union. THELIN has been launched in three member states to date, and will be commercialized in successive EU countries as local government approval for reimbursement is obtained. |
|
| aus der Diskussion: | 42% Plus Ency und die Thelin (TM) Story |
| Autor (Datum des Eintrages): | kaktus10 (16.04.07 08:50:32) |
| Beitrag: | 10 von 12 (ID:28831346) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |